OOIR: Observatory of International Research

Papers

(The H4-Index of Dermatologic Therapy is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Cutaneous signs in COVID ‐19 patients: A review	152
Oral manifestations ofCOVID‐19 disease: A review article	138
COVID ‐19 and economy	107
Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review	76
Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admissi	74
Herpes zoster might be an indicator for latent COVID 19 infection	62
COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study	60
Increased flare of acne caused by long‐time mask wearing during COVID ‐19 pandemic among general population	59
The potential of probiotics for treating acne vulgaris: A review of literature on acne and microbiota	56
Inconveniences due to the use of face masks during the COVID ‐19 pandemic: A survey study of 876 young people	53
The clinics of HHV ‐6 infection in COVID ‐19 pandemic: Pityriasis rosea and Kawasaki disease	53
Challenges of COVID‐19 pandemic for dermatology	49
The effect of the “stay‐at‐home” policy on requests for dermatology outpatient clinic visits after the COVID ‐19 outbreak	47
Cutaneous sıde‐effects of the potential COVID‐19 drugs	47
Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID ‐19 pandemic	47
A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID ‐19: Will cases of psoriasis increase after COV	47
Cutaneous manifestations in hospitalized patients diagnosed as COVID ‐19	46
What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy	46
Back to the basics: Propolis and COVID ‐19	45
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine	44
Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of theCOVID‐19 pandemic	43
Telogen effluvium associated with COVID‐19 infection	42
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study	42
Unraveling the mystery of Covid‐19 cytokine storm: From skin to organ systems	41
Cutaneous manifestations of the Coronavirus Disease 2019 ( COVID ‐19): A brief review	40

COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey duringRED‐ZONEdeclaration	40
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study	39
Covid‐19 and exacerbation of psoriasis	39
Maculopapular eruptions associated to COVID ‐19: A subanalysis of the COVID‐Piel study	39
Urticaria and COVID ‐19: A review	38
The impact of air pollution on skin and related disorders: A comprehensive review	38
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data	37
Cutaneous adverse reactions after COVID ‐19 vaccines in a cohort of 2740 Italian subjects: An observational study	37
Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast	37
The top 10 cosmeceuticals for facial hyperpigmentation	37
Psychodermatology of vitiligo: Psychological impact and consequences	36
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during theCOVID‐19 pandemic	36